CytoMed Therapeutics Ltd Files 20-F for Fiscal Year Ended December 31, 2023

TL;DR

<b>CytoMed Therapeutics Ltd has submitted its 2023 annual report on Form 20-F, detailing its financial performance and corporate information.</b>

AI Summary

CytoMed Therapeutics Ltd (GDTC) filed a Foreign Annual Report (20-F) with the SEC on April 22, 2024. CytoMed Therapeutics Ltd filed its annual report on Form 20-F for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's former name was CytoMed Therapeutics Pte. Ltd., with a name change effective July 16, 2021. CytoMed Therapeutics Ltd is incorporated in U0 and operates in the Pharmaceutical Preparations industry (SIC 2834). The filing was made on April 22, 2024.

Why It Matters

For investors and stakeholders tracking CytoMed Therapeutics Ltd, this filing contains several important signals. This filing provides investors and stakeholders with a comprehensive overview of CytoMed's financial health and operational status for the fiscal year 2023. As a 20-F filing, it offers insights into the company's business, risk factors, and financial statements, crucial for evaluating its investment potential.

Risk Assessment

Risk Level: low — CytoMed Therapeutics Ltd shows low risk based on this filing. The filing is a standard annual report (20-F) and does not contain immediate red flags, indicating a routine disclosure process.

Analyst Insight

Review the detailed financial statements and risk factors within the 20-F filing to assess CytoMed Therapeutics Ltd's performance and future outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (The reporting period concluded on this date.)
• 2024-04-22 — Filing Date (The date the 20-F form was submitted to the SEC.)
• 2021-07-16 — Name Change Date (Effective date of the company's name change.)

Key Players & Entities

• CytoMed Therapeutics Ltd (company) — Filer of the 20-F report
• CytoMed Therapeutics Pte. Ltd. (company) — Former name of the company
• 20-F (regulator) — Form type filed by the company
• 2024-04-22 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end date
• 2021-07-16 (date) — Date of former company name change
• SIC 2834 (industry) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Industry Context

CytoMed Therapeutics Ltd operates within the Pharmaceutical Preparations sector, a highly regulated industry focused on the development and commercialization of drugs.

Regulatory Implications

As a foreign private issuer filing a 20-F, CytoMed Therapeutics Ltd adheres to SEC regulations for annual reporting, providing disclosures relevant to its operations and financial standing.

What Investors Should Do

1. Analyze the financial statements for revenue trends, profitability, and cash flow.
2. Evaluate the risk factors section for potential challenges and mitigation strategies.
3. Compare key financial metrics to previous years to identify performance changes.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 20-F filing.
• 2024-04-22: Filing Date — The date the 20-F was officially submitted.
• 2021-07-16: Name Change — Date when the company changed its name from CytoMed Therapeutics Pte. Ltd.

Year-Over-Year Comparison

This filing represents the annual disclosure for the fiscal year 2023, following previous filings which would have covered prior periods.

Key Financial Figures

• $1.89774 — 09 Ordinary Shares at approximately U.S.$1.89774 per share pursuant to the terms of the

Filing Documents

• form20-f.htm (20-F) — 3947KB
• ex2-1.htm (EX-2.1) — 181KB
• ex11-2.htm (EX-11.2) — 99KB
• ex12-1.htm (EX-12.1) — 14KB
• ex12-2.htm (EX-12.2) — 14KB
• ex13-1.htm (EX-13.1) — 7KB
• ex13-2.htm (EX-13.2) — 7KB
• ex97-1.htm (EX-97.1) — 57KB
• form20-f_001.jpg (GRAPHIC) — 135KB
• form20-f_002.jpg (GRAPHIC) — 27KB
• form20-f_003.jpg (GRAPHIC) — 15KB
• form20-f_004.jpg (GRAPHIC) — 14KB
• form20-f_005.jpg (GRAPHIC) — 30KB
• form20-f_006.jpg (GRAPHIC) — 14KB
• form20-f_007.jpg (GRAPHIC) — 46KB
• form20-f_008.jpg (GRAPHIC) — 27KB
• form20-f_009.jpg (GRAPHIC) — 40KB
• form20-f_010.jpg (GRAPHIC) — 34KB
• form20-f_011.jpg (GRAPHIC) — 39KB
• form20-f_012.jpg (GRAPHIC) — 15KB
• form20-f_013.jpg (GRAPHIC) — 34KB
• form20-f_014.jpg (GRAPHIC) — 39KB
• form20-f_015.jpg (GRAPHIC) — 76KB
• form20-f_016.jpg (GRAPHIC) — 60KB
• form20-f_017.jpg (GRAPHIC) — 39KB
• form20-f_018.jpg (GRAPHIC) — 31KB
• form20-f_019.jpg (GRAPHIC) — 38KB
• form20-f_020.jpg (GRAPHIC) — 44KB
• form20-f_021.jpg (GRAPHIC) — 58KB
• form20-f_022.jpg (GRAPHIC) — 67KB
• form20-f_023.jpg (GRAPHIC) — 63KB
• form20-f_024.jpg (GRAPHIC) — 33KB
• form20-f_025.jpg (GRAPHIC) — 36KB
• form20-f_026.jpg (GRAPHIC) — 29KB
• form20-f_027.jpg (GRAPHIC) — 22KB
• form20-f_028.jpg (GRAPHIC) — 23KB
• form20-f_029.jpg (GRAPHIC) — 23KB
• form20-f_030.jpg (GRAPHIC) — 59KB
• form20-f_031.jpg (GRAPHIC) — 44KB
• aud_001.jpg (GRAPHIC) — 7KB
• aud_002.jpg (GRAPHIC) — 4KB
• 0001493152-24-015594.txt (&nbsp;) — 17789KB
• gdtc-20231231.xsd (EX-101.SCH) — 111KB
• gdtc-20231231_cal.xml (EX-101.CAL) — 110KB
• gdtc-20231231_def.xml (EX-101.DEF) — 318KB
• gdtc-20231231_lab.xml (EX-101.LAB) — 599KB
• gdtc-20231231_pre.xml (EX-101.PRE) — 505KB
• form20-f_htm.xml (XML) — 2853KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS) Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes No TABLE OF CONTENTS Page CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS -ii- DEFINITIONS iii PART I 1 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 1 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 1 ITEM 3. KEY INFORMATION 1 A. [RESERVED] 1 B. CAPITALIZATION AND INDEBTEDNESS 1 C. REASONS FOR THE OFFER AND USE OF PROCEEDS 1 D.

RISK FACTORS

RISK FACTORS 1 ITEM 4. INFORMATION ON THE COMPANY 48 A. HISTORY AND DEVELOPMENT OF THE COMPANY 48 B. BUSINESS OVERVIEW 49 C. ORGANIZATIONAL STRUCTURE 105 D. PROPERTY, PLANTS AND EQUIPMENT 105 ITEM 4A. UNRESOLVED STAFF COMMENTS 105 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 105 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 114 A. DIRECTORS AND SENIOR MANAGEMENT 114 B. COMPENSATION 120 C. BOARD PRACTICES 120 D. EMPLOYEES 122 E. SHARE OWNERSHIP 124 F. DISCLOSURE OF A REGISTRANT'S ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION. 124 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 124 A. MAJOR SHAREHOLDERS 124 B. RELATED PARTY TRANSACTIONS 125 C. INTERESTS OF EXPERTS AND COUNSEL 127 ITEM 8. FINANCIAL INFORMATION 127 ITEM 9. THE OFFER AND LISTING 127 A. OFFERING AND LISTING DETAILS 127 B. PLAN OF DISTRIBUTION 127 C. MARKETS 127 D.

DILUTION

DILUTION 127 E. EXPENSE OF THE ISSUE 127 ITEM 10. ADDITIONAL INFORMATION 128 A. SHARE CAPITAL 128 B. CONSTITUTION OF THE COMPANY 128 C. MATERIAL CONTRACTS 128 D. EXCHANGE CONTROLS 128 E. TAXATION 128 F. DIVIDENDS AND PAYING AGENTS 134 G. 134 H. DOCUMENTS ON DISPLAY 134 I. SUBSIDIARY INFORMATION 134 J. ANNUAL REPORT TO SECURITY HOLDERS 134 ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 134 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 135 PART II 135 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 135 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 135 A-D. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS 135 E.

USE OF PROCEEDS

USE OF PROCEEDS 135 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 135 ITEM 16. RESERVED 136 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 136 ITEM 16B. CODE OF ETHICS 136 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 136 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 136 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 136 ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 137 ITEM 16G. CORPORATE GOVERNANCE 137 ITEM 16H. MINE SAFETY DISCLOSURE 137 ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 137 ITEM 16J. INSIDER TRADING POLICIES 137 ITEM 16K. CYBERSECURITY 137 PART III 138 ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 138 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 138 ITEM 19. EXHIBITS 138 -i- CAUTIONARY This annual report contains certain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on our beliefs and assumptions and on information currently available to us, and include, without limitation, statements regarding our business, financial condition, strategy, results of operations, certain of our plans, objectives, assumptions, expectations, prospects and beliefs and statements regarding other future events or prospects. Forward-looking as the words "believe", "expect", "plan", "intend", "seek", "anticipate", "estimate", "predict", "potential", "assume", "continue", "may", "will", "should", "could", "shall", "risk" or the negative of these terms or similar expressions that are predictions of or indicate future events and future trends. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, the development of the industry in which we operate and the effect of acquisitions on us may differ materially from those made in or suggested by the forward-looking statements contained in this annual report. In addition, even if our results of operations, financial condition and liquidity, the development of the industry in which we operate and the effect of acquisitions on us are consistent with the forward-looking statements contained in this annual report, those results or developments may not be indicative of results or developme

View Full Filing

View this 20-F filing on SEC EDGAR